Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with Respiratory Comorbidities: Results from the Phase 3 NAVIGATOR Study
The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology(2022)
摘要
Tezepelumab is a human monoclonal antibody that targets thymic stromal lymphopoietin (TSLP). The phase 3 NAVIGATOR study (NCT03347279) investigated the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. This post hoc analysis evaluated the efficacy of tezepelumab in patients from NAVIGATOR with specific respiratory comorbidities of interest.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要